Clinicians may counsel patients towards therapies with lower efficacy if the dosing schedule is more convenient (e.g., quarterly). The rationale is that a lack of response is evident quickly, allowing a rapid pivot to another treatment without losing significant time or risking progression.

Experts admit to preferring docetaxel chemotherapy over lutetium for symptomatic mCRPC patients primarily because it 'feels' more aggressive and is logistically faster to administer. This decision is based on perception and convenience rather than strong clinical evidence comparing the agents in this specific context.

The widely used and effective off-label combination of gemcitabine/docetaxel is rarely administered in community settings. The inexpensive drugs and long patient chair time make it a financial loss for these practices, creating an economic, not clinical, barrier to a viable treatment.

Despite new therapies for follicular lymphoma (FL), bendamustine-rituximab (BR) will likely remain the community standard due to its simplicity. This may create a growing gap in treatment approaches between academic centers using novel agents and community practices favoring the familiar BR regimen.

In the AMPLITUDE trial, only 16% of high-risk metastatic prostate cancer patients received docetaxel, despite it being allowed and indicated by disease characteristics. This suggests a real-world "chemophobia" or physician bias towards newer targeted therapies, even within a clinical trial setting.

Effective new antibiotics are used sparingly to prevent resistance, which makes them commercially unviable for pharma companies. This "vicious circle" of low usage leading to low revenue actively disincentivizes the development of the very drugs needed to combat superbugs.

Advanced diagnostics like Signatera ctDNA and therapies such as adjuvant nivolumab, while becoming standard in the US, are often unavailable in Europe and elsewhere. This creates a significant gap in care, making many cutting-edge discussions purely theoretical for a large portion of the world's oncologists and patients.

Despite guidelines and trial data suggesting low-volume patients may not benefit from chemotherapy, some oncologists offer it to a select subset. This decision is based on factors like young age, fitness, and genomic alterations in tumor suppressor genes, reflecting a personalized, biology-driven approach in an area where consensus is lacking.

The lack of randomized trials comparing new bladder cancer drugs to the standard of care, gemcitabine-docetaxel, isn't just about cost. There's an underlying fear within pharmaceutical companies that their expensive new agents may not prove superior to the highly effective and inexpensive 'gemdose,' stalling meaningful progress.